Literature DB >> 26459826

Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model.

Stuart D Dowall1, Andrew Bosworth1, Robert Watson1, Kevin Bewley1, Irene Taylor1, Emma Rayner1, Laura Hunter1, Geoff Pearson1, Linda Easterbrook1, James Pitman1, Roger Hewson1, Miles W Carroll1.   

Abstract

Ebola virus (EBOV) is highly pathogenic, with a predisposition to cause outbreaks in human populations accompanied by significant mortality. Owing to the lack of approved therapies, screening programmes of potentially efficacious drugs have been undertaken. One of these studies has demonstrated the possible utility of chloroquine against EBOV using pseudotyped assays. In mouse models of EBOV disease there are conflicting reports of the therapeutic effects of chloroquine. There are currently no reports of its efficacy using the larger and more stringent guinea pig model of infection. In this study we have shown that replication of live EBOV is impaired by chloroquine in vitro. However, no protective effects were observed in vivo when EBOV-infected guinea pigs were treated with chloroquine. These results advocate that chloroquine should not be considered as a treatment strategy for EBOV.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26459826      PMCID: PMC5410110          DOI: 10.1099/jgv.0.000309

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  51 in total

1.  Emergence of Zaire Ebola virus disease in Guinea.

Authors:  Sylvain Baize; Delphine Pannetier; Lisa Oestereich; Toni Rieger; Lamine Koivogui; N'Faly Magassouba; Barrè Soropogui; Mamadou Saliou Sow; Sakoba Keïta; Hilde De Clerck; Amanda Tiffany; Gemma Dominguez; Mathieu Loua; Alexis Traoré; Moussa Kolié; Emmanuel Roland Malano; Emmanuel Heleze; Anne Bocquin; Stephane Mély; Hervé Raoul; Valérie Caro; Dániel Cadar; Martin Gabriel; Meike Pahlmann; Dennis Tappe; Jonas Schmidt-Chanasit; Benido Impouma; Abdoul Karim Diallo; Pierre Formenty; Michel Van Herp; Stephan Günther
Journal:  N Engl J Med       Date:  2014-04-16       Impact factor: 91.245

Review 2.  The anti-HIV-1 activity of chloroquine.

Authors:  A Savarino; L Gennero; K Sperber; J R Boelaert
Journal:  J Clin Virol       Date:  2001-02       Impact factor: 3.168

3.  Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.

Authors:  Kartik Chandran; Nancy J Sullivan; Ute Felbor; Sean P Whelan; James M Cunningham
Journal:  Science       Date:  2005-04-14       Impact factor: 47.728

Review 4.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

5.  Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA.

Authors:  Sandra S Diebold; Tsuneyasu Kaisho; Hiroaki Hemmi; Shizuo Akira; Caetano Reis e Sousa
Journal:  Science       Date:  2004-02-19       Impact factor: 47.728

6.  A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults.

Authors:  Vianney Tricou; Nguyet Nguyen Minh; Toi Pham Van; Sue J Lee; Jeremy Farrar; Bridget Wills; Hien Tinh Tran; Cameron P Simmons
Journal:  PLoS Negl Trop Dis       Date:  2010-08-10

7.  Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy.

Authors:  Matteo Porotto; Gianmarco Orefice; Christine C Yokoyama; Bruce A Mungall; Ronald Realubit; Michael L Sganga; Mohamad Aljofan; Michael Whitt; Fraser Glickman; Anne Moscona
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

8.  Elucidating variations in the nucleotide sequence of Ebola virus associated with increasing pathogenicity.

Authors:  Stuart D Dowall; David A Matthews; Isabel Garcia-Dorival; Irene Taylor; John Kenny; Christiane Hertz-Fowler; Neil Hall; Kara Corbin-Lickfett; Cyril Empig; Kyle Schlunegger; John N Barr; Miles W Carroll; Roger Hewson; Julian A Hiscox
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

Review 9.  Effects of chloroquine on viral infections: an old drug against today's diseases?

Authors:  Andrea Savarino; Johan R Boelaert; Antonio Cassone; Giancarlo Majori; Roberto Cauda
Journal:  Lancet Infect Dis       Date:  2003-11       Impact factor: 25.071

10.  Chloroquine is effective against influenza A virus in vitro but not in vivo.

Authors:  David J Vigerust; Jonathan A McCullers
Journal:  Influenza Other Respir Viruses       Date:  2007 Sep-Nov       Impact factor: 4.380

View more
  54 in total

1.  Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19.

Authors:  Ahmed Awad Adeel
Journal:  Sudan J Paediatr       Date:  2020

2.  Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig.

Authors:  Thomas R Lane; Christopher Massey; Jason E Comer; Alexander N Freiberg; Huanying Zhou; Julie Dyall; Michael R Holbrook; Manu Anantpadma; Robert A Davey; Peter B Madrid; Sean Ekins
Journal:  Antiviral Res       Date:  2020-07-16       Impact factor: 5.970

Review 3.  Severe Acute Respiratory Syndrome Coronavirus 2: Genomic Observations and Emerging Therapies.

Authors:  Walter Dehority; Dominique Spence; Darrell L Dinwiddie
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2020-05-06       Impact factor: 0.885

4.  Defending Antiviral Cationic Amphiphilic Drugs That May Cause Drug-Induced Phospholipidosis.

Authors:  Thomas R Lane; Sean Ekins
Journal:  J Chem Inf Model       Date:  2021-09-13       Impact factor: 6.162

5.  Minimal In Vivo Efficacy of Iminosugars in a Lethal Ebola Virus Guinea Pig Model.

Authors:  Joanna L Miller; Simon G Spiro; Stuart D Dowall; Irene Taylor; Antony Rule; Dominic S Alonzi; Andrew C Sayce; Edward Wright; Emma M Bentley; Ruth Thom; Graham Hall; Raymond A Dwek; Roger Hewson; Nicole Zitzmann
Journal:  PLoS One       Date:  2016-11-23       Impact factor: 3.240

6.  Simple rapid in vitro screening method for SARS-CoV-2 anti-virals that identifies potential cytomorbidity-associated false positives.

Authors:  Kexin Yan; Daniel J Rawle; Thuy T Le; Andreas Suhrbier
Journal:  Virol J       Date:  2021-06-09       Impact factor: 4.099

7.  Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues.

Authors:  Leentje Persoons; Evelien Vanderlinden; Laura Vangeel; Xinyu Wang; Nguyen Dan Thuc Do; Shi-Yan Caroline Foo; Pieter Leyssen; Johan Neyts; Dirk Jochmans; Dominique Schols; Steven De Jonghe
Journal:  Antiviral Res       Date:  2021-07-01       Impact factor: 5.970

8.  Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review.

Authors:  Hussein Sweiti; Obinna Ekwunife; Thomas Jaschinski; Stefan K Lhachimi
Journal:  Curr Ther Res Clin Exp       Date:  2017-02-02

Review 9.  Discovering Drugs for the Treatment of Ebola Virus.

Authors:  Sandra L Bixler; Allen J Duplantier; Sina Bavari
Journal:  Curr Treat Options Infect Dis       Date:  2017-08-04

10.  Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials.

Authors:  Augusto Di Castelnuovo; Simona Costanzo; Antonio Cassone; Roberto Cauda; Giovanni De Gaetano; Licia Iacoviello
Journal:  Pathog Glob Health       Date:  2021-06-15       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.